Our data suggests that TFAP2C and PELP1 signaling plays a role in ER+ BC progression and that the PELP1 dysregulation, commonly seen in breast tumors, may contribute to enhanced TFAP2C oncogenic signaling. The gene discussed is PELP1; the disease is breast cancer.